Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

August 16, 1999

In Re: LORAZEPAM/CLORAZE, et al v. MYLAN LABORATORIES, et al

Track this case

Case Number:

1:99-mc-00276

Court:

District Of Columbia

Nature of Suit:

890 Other Statutory Actions

Judge:

Thomas F. Hogan

Firms

Companies

Government Agencies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. August 31, 2017

    Mylan, Other Drugmakers Must Pay $67M In Antitrust Suit

    The D.C. federal court has ordered generic-drug maker Mylan Pharmaceuticals and chemical companies Cambrex and Gyma Laboratories to pay a combined $67 million to Blue Cross Blue Shield of Massachusetts and three other insurers in a long-running suit accusing the three companies of violating state antitrust laws.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login